Peps
What is Pasireotide?
Pasireotide is a somatostatin analogue studied in Cushing disease. The selected trial measured cortisol control and reported frequent hyperglycemia-related events.
Biological role or research focus
Cushing disease research.
A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Role reference: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
- Class / identity
- Somatostatin analogue
- Research focus
- Cushing disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Molecular structure
How Pasireotide works
Pasireotide engages somatostatin receptor pathways. In Cushing disease, the treatment strategy aims to alter hormone secretion; biochemical response and clinical outcomes remain separate measurements.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Medicine status & clinical context
Pasireotide medicines are used for specified Cushing’s disease and acromegaly populations when surgery is unsuitable or unsuccessful. Signifor and Signifor LAR have formulation-dependent indications; results should remain attached to the product actually studied.
The selected report concerns adults with Cushing disease. Current product labels are needed for precise indications, formulations, and monitoring requirements.
Source: MedlinePlus · Pasireotide injection ↗
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
Pasireotide Cushing disease phase 3 study
How many participants achieved cortisol control, and what harms occurred?
- Population / model
- 162 adults with Cushing disease.
- Study design
- Double-blind phase 3 comparison of two pasireotide regimens, with an open-label period through 12 months; no placebo arm.
- Main finding
- At month six, urinary cortisol normalized without an increase in the assigned regimen in 12 of 82 and 21 of 80 participants. Hyperglycemia-related adverse events occurred in 118 of 162; 74 started glucose-lowering medication.
- Limits & context
- A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Acromegaly. ↗
Nature reviews. Disease primers · 2019 Mar 21 · Journal Article, Review
Pasireotide. ↗
· 2012 · Review
Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. ↗
Endocrine reviews · 2026 May 13 · Journal Article, Review
Read available full text ↗
Pasireotide. ↗
· 2006 · Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Hyperglycemia is a central concern in this publication. The high event frequency should remain visible alongside cortisol results; current labeling supplies the complete precautions.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Identity, route, and evidence limits
A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Does normalized cortisol mean everyone was cured?
- What population, comparator, and route were actually studied?
- A biochemical response in a subset is not a cure for every patient. The trial compared two regimens rather than treatment with placebo. Novartis funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does normalized cortisol mean everyone was cured?
No. Only a subset met the specified endpoint, and biochemical control is different from resolution of all symptoms or long-term complications.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: A 12-month phase 3 study of pasireotide in Cushing's disease. · 2012 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.